1. Ptehoosines A and B: Two new sesamin-type sesquilignans with antiangiogenic activity from Pterocephalus hookeri (C.B. Clarke) Höeck
- Author
-
Fan-Cheng Meng, Zhihua Liao, Guo-Wei Wang, Min Chen, Qing-Hong Zeng, Lin Wei, Hui-Qiang Lu, Xiaozhong Lan, and Zhaoyue Dong
- Subjects
Angiogenesis ,Phytochemicals ,Angiogenesis Inhibitors ,Dioxoles ,Pharmacology ,Tibet ,01 natural sciences ,Caprifoliaceae ,Umbilical vein ,Lignans ,chemistry.chemical_compound ,Sesamin ,Drug Discovery ,Human Umbilical Vein Endothelial Cells ,Animals ,Humans ,Medicine, Tibetan Traditional ,Pterocephalus hookeri ,IC50 ,Zebrafish ,Molecular Structure ,010405 organic chemistry ,General Medicine ,Cell Cycle Checkpoints ,Cell cycle ,In vitro ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,Antiangiogenic effect ,chemistry - Abstract
Two undescribed sesamin-type sesquilignans ptehoosines A (1) and B (2), together with 4 known lignans (3–6), were isolated from Pterocephalus hookeri (C.B. Clarke) Hoeck which was widely used as traditional Tibetan medicine for treatment of rheumatoid arthritis. Their structures were determined by HR-ESI-MS, NMR analysis and CD experiment. The in vitro antiangiogenic effect of all isolated compounds against human umbilical vein endothelial cells (HUVECs) were evaluated by CCK-8 assay. Among them, compound 1 exhibited significant proliferative inhibition on HUVECs with IC50 value of 32.82 ± 0.99 μM. Further in vitro study indicated 1 could arrest cell cycle at G0/G1 phase and reduce the migration of HUVECs. In vivo experiment exhibited 1 could inhibit tail vessels plexus in zebrafish. The above finding suggested that 1 was a promising lead compound against RA by inhibiting of angiogenesis.
- Published
- 2021